Minerva Neurosciences
Open
$6.47
Prev. Close
$6.48
High
$6.48
Low
$6.44
Market Snapshot
$44.69M
-0.2
0.19
7
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
emptyResult
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Recently from Cashu
Please provide the content you'd like summarized, and I will create a title for you.
Sure! Please provide the text you would like me to summarize, and I'll create a 300-word paragraph for you.
Please provide the content you'd like summarized, and I'll create a title for you.
Sure! Please provide the text you'd like me to summarize into a 300-word paragraph.
Minerva Neurosciences: Innovative Approaches in Neurological Disorder Treatments
Please provide the text you'd like me to summarize into a 300-word article, and I will be happy to assist you.
Minerva Neurosciences Partners with Aidoc to Enhance Neurodiagnostic Capabilities and Patient Care
Advancing Neurodiagnostic Capabilities through Strategic Partnerships Aidoc, a leader in clinical AI technology, forges strategic partnerships with Cercare Medical and Circle CVI to enhance its neuros…